Skip to content
value.today

Deka Biosciences, Inc.

🇺🇸 Germantown, Maryland, USABiotechnologyFounded 2018

Formerly Alli Biosciences, Inc.

Total raised
$46 M
2 rounds on record
Latest round
$30 M
Feb 2023
First round on record
Oct 2021
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Deka Biosciences, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Feb 2023$30 MNo. 2$10 to $50 million

Deka Biosciences, Inc.: Raise no. 2, Feb 2023

Investors in this round

33 investors had bought by the notice of Dec 8, 2023: 33 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$30 M of $41 M offered; $12 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christopher Yaen · Executive Officer
  • John Mumm · Executive Officer, Director
  • Pavel Khrimian · Executive Officer
  • Detlev Biniszkiewicz · Director
  • Lu Han · Director
  • Peter Buzy · Director
  • Rakhshita Dhar · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by John Mumm, Chief Executive Officer. Source: SEC Form D, newest notice filed Dec 8, 2023. Read the notice at the SEC.

equitySEC
Oct 2021$16 MNo. 1$10 to $50 million

Deka Biosciences, Inc.: Raise no. 1, Oct 2021

Investors in this round

28 investors had bought by the notice of Nov 23, 2021: 28 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$16 M of $26 M offered; $10 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John Mumm · Executive Officer, Director
  • Pavel Khrimian · Executive Officer, Director
  • Vera Mumm · Executive Officer
  • Christian Kanady · Director
  • Lu Han · Director
  • Lucio Iannone · Director
  • Sally (Yuanheng) Wang · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Total amount sold includes the value of cancelled indebtedness formerly held by certain purchasers in the aggregate principal and interest amount of approximately $5,886,661.92”

Signed by John Mumm, Chief Executive Officer. Source: SEC Form D, newest notice filed Nov 23, 2021. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Deka Biosciences, Inc. chose not to state its revenue in its newest notice of a funding round (Dec 2023).

    SEC Form D · Dec 2023

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Dec 2023

That is all the official record says: Deka Biosciences, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Deka Biosciences, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 33 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Deka Biosciences, Inc.
NameRoleNamed in
Christopher YaenExecutive officerDec 2023
John MummExecutive officerDec 2023
Pavel KhrimianExecutive officerDec 2023
Vera MummExecutive officerNov 2021
Detlev BiniszkiewiczDirectorDec 2023
John MummDirectorDec 2023
Lu HanDirectorDec 2023
Peter BuzyDirectorDec 2023
Rakhshita DharDirectorDec 2023
Christian KanadyDirectorNov 2021
Lucio IannoneDirectorNov 2021
Pavel KhrimianDirectorNov 2021
Sally (Yuanheng) WangDirectorNov 2021